Overview

A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients

Status:
Completed

Trial end date:
2011-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the antiviral activity as measured by the change in viral load from baseline in the 14 days following initiation of treatment with 4 different dose regimens of TMC310911 co-administered with ritonavir.

Phase:

Phase 2

Details

Lead Sponsor:

Tibotec Pharmaceuticals, Ireland

Treatments:

Antiviral Agents
Ritonavir
TMC-310911